STOCK TITAN

Quest Diagnostics Inc. - DGX STOCK NEWS

Welcome to our dedicated page for Quest Diagnostics news (Ticker: DGX), a resource for investors and traders seeking the latest updates and insights on Quest Diagnostics stock.

Quest Diagnostics Inc. (NYSE: DGX) is a leading provider of diagnostic testing, information, and services in the United States, enabling people to make informed health decisions. The company provides diagnostic insights derived from the world’s largest database of clinical lab results, which aids in identifying and treating diseases, promoting healthy behaviors, and improving healthcare management.

Quest Diagnostics serves one in three adult Americans and half of the physicians and hospitals in the United States. Its workforce of nearly 50,000 employees is dedicated to transforming lives by providing actionable diagnostic insights. The company offers the broadest test menu available, with over 3,000 different tests, and has a strong focus on cancer diagnostics, anatomic pathology, and interpretive consultations through its medical and scientific staff of approximately 900 M.D.s and Ph.D.s.

In recent years, Quest Diagnostics has been at the forefront of innovation in diagnostic testing. The company has significantly invested in AI and digital pathology to enhance the accuracy and efficiency of cancer diagnoses. A notable collaboration with PathAI aims to accelerate the adoption of digital and AI pathology technologies, thereby improving the quality, speed, and efficiency of diagnosing cancer and other diseases. This partnership includes the acquisition of PathAI Diagnostics’ state-of-the-art digitized laboratory in Memphis, Tennessee, which will serve as Quest’s AI and digital R&D and solutions center.

Financially, Quest Diagnostics has shown robust performance, with annual revenues reaching $7.4 billion in 2014. The company continues to strengthen its market presence through strategic acquisitions and partnerships, expanding its services and enhancing its capabilities in specialized pathology services. The integration of digital and AI technologies across its operations has improved quality, efficiency, and customer satisfaction, positioning Quest Diagnostics as a leader in the diagnostic services industry.

Quest Diagnostics' extensive clinical testing network includes roughly 2,300 patient service centers, numerous doctors' offices, and hospitals nationwide. The company also provides clinical trials testing, risk assessment services, and information technology solutions through its diagnostic solutions segment.

By leveraging its comprehensive diagnostic insights, Quest Diagnostics aims to empower individuals and healthcare providers to make informed decisions that lead to better health outcomes, ultimately contributing to a healthier world.

Rhea-AI Summary

Quest Diagnostics and PathAI announced a collaboration to accelerate AI and digital pathology adoption in cancer diagnosis. Quest will acquire certain assets of PathAI Diagnostics to enhance its AI and digital capabilities. The transaction includes licensing agreements and is expected to close in Q2 2024. The partnership aims to improve cancer care quality and efficiency with cutting-edge technologies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.46%
Tags
-
Rhea-AI Summary

The Quest Diagnostics Foundation and Green Bronx Machine have expanded their collaboration to bring indoor gardening curriculum to more communities. The foundation grant will help extend the reach of Green Bronx Machine's school-based model to 50 schools in Baltimore and Houston, highlighting the importance of nutrition education for health equity. The initiative is part of the Quest for Health Equity (Q4HE) program, supporting under-resourced schools and communities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
none
-
Rhea-AI Summary
Quest Diagnostics reported first quarter 2024 financial results with revenues of $2.37 billion, up 1.5% from 2023. Adjusted diluted EPS remained flat at $2.04. The company raised full-year revenue guidance to $9.40-$9.48 billion and adjusted diluted EPS to $8.72-$8.97.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.08%
Tags
Rhea-AI Summary
Quest Diagnostics announces the addition of a new blood biomarker test for phosphorylated tau 217 (p-tau217) to its AD-Detect™ portfolio, aimed at assessing the risk and aiding in the early diagnosis of Alzheimer's Disease. The test complements existing blood tests for AD biomarkers, offering patients and providers a comprehensive approach to brain health evaluation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.28%
Tags
none
-
Rhea-AI Summary
Quest for Health Equity (Q4HE) receives recognition for its efforts to reduce health disparities in Baltimore City. The initiative, funded by Quest Diagnostics Foundation, collaborates with the Y in Central Maryland to strengthen healthy equity coalition efforts. The joint project focuses on care coordination, mental and behavioral health, chronic disease prevention, and community-based partnerships aligned with addressing health disparities. Quest Diagnostics also offers Blueprint for Wellness testing at select community events to empower individuals with health knowledge.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.09%
Tags
none
-
News
Rhea-AI Summary
Quest Diagnostics employee shares their journey of joining the company as a courier, highlighting the supportive work environment and personal growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.08%
Tags
none
Rhea-AI Summary
Quest Diagnostics (DGX) and Broad Clinical Labs collaborate to showcase the clinical value of whole genome sequencing (WGS) as a primary genetic test for developmental delay disorders. The research aims to prove that WGS can offer accurate insights from a single blood test, potentially replacing multiple conventional tests, leading to faster diagnoses and reduced costs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.84%
Tags
none
-
News
Rhea-AI Summary
Quest Diagnostics driver shares her journey from part-time to full-time employment, highlighting dedication and commitment to the company's mission and customer service.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
none
-
Rhea-AI Summary
Quest Diagnostics employee Marissa McGhee receives praise for her exceptional patient care during a life insurance paramedical exam in Stamford, Connecticut. The patient commended Marissa for her customer-first approach and attentiveness during the exam, highlighting her professionalism and ability to handle a potentially concerning situation with ease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.32%
Tags
none
Rhea-AI Summary
Quest Diagnostics, in collaboration with the University of Florida and Mount Sinai Medical Center, has developed a blood test that can potentially reduce the need for PET imaging in patients with mild cognitive impairment, aiding in the diagnosis of non-Alzheimer's disease causes and cutting healthcare costs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.32%
Tags
none

FAQ

What is the current stock price of Quest Diagnostics (DGX)?

The current stock price of Quest Diagnostics (DGX) is $153.1 as of December 20, 2024.

What is the market cap of Quest Diagnostics (DGX)?

The market cap of Quest Diagnostics (DGX) is approximately 17.0B.

What does Quest Diagnostics do?

Quest Diagnostics provides diagnostic testing, information, and services that help healthcare providers and patients make informed health decisions. The company offers a broad range of tests and diagnostic insights derived from the world’s largest database of clinical lab results.

How many people does Quest Diagnostics serve annually?

Quest Diagnostics serves one in three adult Americans and half of the physicians and hospitals in the United States each year.

What are some recent achievements of Quest Diagnostics?

Recently, Quest Diagnostics has partnered with PathAI to enhance its AI and digital pathology capabilities. The acquisition of PathAI Diagnostics' digital laboratory will serve as a new AI and digital R&D center, improving cancer diagnosis quality and efficiency.

What kind of tests does Quest Diagnostics offer?

Quest Diagnostics offers over 3,000 different tests, including clinical testing, anatomic pathology, esoteric testing, and substance abuse testing.

What is the company's approach to innovation?

Quest Diagnostics focuses on incorporating AI and digital technologies into its diagnostic services to enhance accuracy, efficiency, and accessibility of its offerings. The company also pilots new technologies and expands its capabilities through strategic partnerships and acquisitions.

How extensive is Quest Diagnostics' clinical testing network?

Quest Diagnostics operates an extensive clinical testing network with approximately 2,300 patient service centers, as well as numerous doctor’s offices and hospitals across the United States.

What role do partnerships play at Quest Diagnostics?

Partnerships, such as the recent collaboration with PathAI, play a crucial role in Quest Diagnostics' strategy to integrate advanced technologies and expand its capabilities in specialized diagnostic services.

How does Quest Diagnostics contribute to healthcare management?

Quest Diagnostics provides diagnostic insights that help identify and treat diseases, inspire healthy behaviors, and improve healthcare management. These insights support more informed decision-making by both patients and healthcare providers.

What are the company’s future plans?

Quest Diagnostics plans to continue expanding its capabilities in AI and digital pathology, enhance its clinical testing services, and maintain its leadership in diagnostic information services. The company aims to leverage its diagnostic insights to empower better healthcare outcomes globally.

How does Quest Diagnostics ensure the quality of its services?

Quest Diagnostics employs nearly 50,000 dedicated professionals, including about 900 M.D.s and Ph.D.s, and integrates cutting-edge technology and rigorous quality control measures across its operations to ensure high-quality diagnostic services.

Quest Diagnostics Inc.

NYSE:DGX

DGX Rankings

DGX Stock Data

16.99B
111.10M
0.43%
91.55%
2.32%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
SECAUCUS